Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
Sensei Biotherapeutics (NASDAQ: SNSE) has announced an upcoming presentation of clinical data at the ESMO Congress 2025 in Berlin, Germany. The presentation will focus on results from the Phase 1 dose expansion cohort studying solnerstotug, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® (cemiplimab).
The study specifically examines patients with advanced solid tumors resistant to prior PD-(L)1 therapy. Dr. Kyriakos Papadopoulos from START, San Antonio will present the findings on October 17, 2025 during a mini oral session.
Sensei Biotherapeutics (NASDAQ: SNSE) ha annunciato una prossima presentazione di dati clinici al Congresso ESMO 2025 che si terrà a Berlino, Germania. La presentazione si concentrerà sui risultati del coorte di espansione della dose di Fase 1 che studia solnerstotug, sia come monoterapia che in combinazione con l'inibitore PD-1 Libtayo® (cemiplimab) di Regeneron.
Lo studio esamina specificamente pazienti con tumori solidi avanzati resistenti a precedenti terapie PD-(L)1. Il dott. Kyriakos Papadopoulos di START, San Antonio, presenterà i risultati il 17 ottobre 2025 durante una mini sessione orale.
Sensei Biotherapeutics (NASDAQ: SNSE) ha anunciado una próxima presentación de datos clínicos en el Congreso ESMO 2025 en Berlín, Alemania. La presentación se centrará en los resultados de la cohorte de expansión de dosis de Fase 1 que estudia solnerstotug, tanto como monoterapia como en combinación con el inhibidor de PD-1 Libtayo® (cemiplimab) de Regeneron.
El estudio examina específicamente a pacientes con tumores sólidos avanzados resistentes a terapias previas PD-(L)1. El Dr. Kyriakos Papadopoulos de START, San Antonio, presentará los hallazgos el 17 de octubre de 2025 durante una mini sesión oral.
Sensei Biotherapeutics (NASDAQ: SNSE)는 독일 베를린에서 열리는 ESMO Congress 2025에서 임상 데이터 발표를 예정하고 있습니다. 발표는 1상 용량 확장 코호트에서 연구한 solnerstotug의 단독 요법 및 Regeneron의 PD-1 억제제 Libtayo®(cemiplimab)와의 병용 요법 결과에 중점을 둘 예정입니다.
이 연구는 이전 PD-(L)1 치료에 내성을 보이는 진행성 고형 종양 환자를 대상으로 합니다. START, 샌안토니오의 Kyriakos Papadopoulos 박사가 2025년 10월 17일 미니 구두 세션에서 연구 결과를 발표할 예정입니다.
Sensei Biotherapeutics (NASDAQ : SNSE) a annoncé une prochaine présentation de données cliniques lors du Congrès ESMO 2025 à Berlin, en Allemagne. La présentation portera sur les résultats de la cohorte d'expansion de dose de phase 1 étudiant le solnerstotug, à la fois en monothérapie et en association avec l'inhibiteur PD-1 Libtayo® (cemiplimab) de Regeneron.
L'étude porte spécifiquement sur des patients atteints de tumeurs solides avancées résistantes à une thérapie PD-(L)1 antérieure. Le Dr Kyriakos Papadopoulos de START, San Antonio, présentera les résultats le 17 octobre 2025 lors d'une mini session orale.
Sensei Biotherapeutics (NASDAQ: SNSE) hat eine bevorstehende Präsentation klinischer Daten auf dem ESMO Kongress 2025 in Berlin, Deutschland, angekündigt. Die Präsentation wird sich auf Ergebnisse der Phase-1-Dosis-Erweiterungsgruppe konzentrieren, die solnerstotug sowohl als Monotherapie als auch in Kombination mit Regenerons PD-1-Inhibitor Libtayo® (cemiplimab) untersucht.
Die Studie untersucht speziell Patienten mit fortgeschrittenen soliden Tumoren, die gegen vorherige PD-(L)1-Therapien resistent sind. Dr. Kyriakos Papadopoulos von START, San Antonio, wird die Ergebnisse am 17. Oktober 2025 während einer kurzen mündlichen Sitzung vorstellen.
- None.
- None.
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21, 2025 in Berlin, Germany.
Presentation Details:
Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD-(L)1 therapy
Presenter: Dr. Kyriakos Papadopoulos, Co-Director of Clinical Research at START, San Antonio
Abstract Number: 3933
Presentation Date & Time: Friday, October 17, 2025 from 2:00 – 3:30 CEST
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor & Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When will Sensei Biotherapeutics (SNSE) present its solnerstotug clinical data at ESMO 2025?
What is the focus of Sensei Biotherapeutics' (SNSE) Phase 1 clinical trial presentation?
Who will present Sensei Biotherapeutics' (SNSE) clinical trial results at ESMO 2025?
What type of cancer treatment is Sensei Biotherapeutics (SNSE) developing?
